Eurican DHPPi
Active substance
ATC code
Species
Dogs.
Indications
Active immunisation of dogs to:
- prevent mortality and clinical signs caused by canine distemper virus (CDV),
- prevent mortality and clinical signs caused by infectious canine hepatitis virus (CAV),
- reduce viral excretion during respiratory disease caused by canine
adenovirus type 2 (CAV-2),
- prevent mortality, clinical signs and viral excretion caused by canine parvovirus (CPV)*,
- reduce viral excretion caused by canine parainfluenza virus type 2 (CPiV),
Onset of immunity: 2 weeks for all strains
Duration of immunity: at least one year after the second injection of the primary vaccination course for all strains.
Current available challenge and serological data show that protection for distemper virus, adenovirus and parvovirus* lasts for 2 years after primary vaccination course followed by a first annual booster.
Any decision to adapt the vaccination schedule of this veterinary medicinal product needs to be made on a case by case basis, taking into account the vaccination history of the dog and the epidemiological context.
*Protection has been demonstrated against canine parvovirus type 2a, 2b and 2c either by challenge (type 2b) or serology (type 2a and 2c).
Dose to be administered and administration route
Aseptically reconstitute the contents of the lyophilisate with a compatible Boehringer Ingelheim vaccine (Eurican LR, Eurican L or Eurican Lmulti) where available. Shake well before use. The entire contents of the reconstituted vial should be administered as a single dose. The reconstituted contents shall be an opalescent yellow to orange suspension.
Inject a 1-ml dose subcutaneously according to the following schedule:
Primary vaccination:
Two injections separated by an interval of 4 weeks from 7 weeks of age. When administered with Boehringer Ingelheim's vaccines containing rabies, the minimum age for vaccination is 12 weeks of age.
In cases where high levels of maternally derived antibodies are suspected by the veterinarian and the primary vaccination course was completed before 16 weeks of age, a third injection using a Boehringer Ingelheim vaccine containing Distemper, Adenovirus and Parvovirus is recommended from 16 weeks of age, at least 3 weeks after the second injection.
Revaccination: Administer one dose 12 months after completion of the primary vaccination course. Dogs should be revaccinated with a single booster dose on an annual basis.
Adverse reactions
Immediately after injection, a slight swelling (≤ 2 cm) may commonly be observed at the injection site, usually regressing within 1-6 days. This can, on some occasions, be accompanied by slight pruritus, heat and pain at the injection site. Transient lethargy and emesis may also be commonly observed.
Uncommon reactions such as anorexia, polydipsia, hyperthermia, diarrhoea, muscle tremor, muscle weakness and injection site cutaneous lesions may be observed.
As with any vaccine, rare hypersensitivity reactions may occur. In such cases, appropriate symptomatic treatment should be provided.
The frequency of adverse reactions is defined using the following convention:
- very common (more than 1 in 10 animals displaying adverse reaction(s) during the course of one treatment)
- common (more than 1 but less than 10 animals in 100 animals)
- uncommon (more than 1 but less than 10 animals in 1,000 animals)
- rare (more than 1 but less than 10 animals in 10,000 animals)
- very rare (less than 1 animal in 10,000 animals, including isolated reports).
| PRICE | Only for registered vets. Create a free profile to access all features.. Login |
|---|---|
| Art. Nr. | 08327/4126 |
| EAN | 3661103006039 |
